CUTR stock icon

Cutera
CUTR

$0.6870
6.64%

Market Cap: $13.8M

 

About: Cutera Inc is a medical device company. It specializes in the design, development, manufacture, marketing and servicing of laser and other energy based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States geographic segment.

Employees: 430

0
Funds holding %
of 6,686 funds
0
Analysts bullish %
of 4 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

10% less funds holding

Funds holding: 88 [Q1] → 79 (-9) [Q2]

15.2% less ownership

Funds ownership: 68.03% [Q1] → 52.84% (-15.2%) [Q2]

20% less capital invested

Capital invested by funds: $20M [Q1] → $16M (-$3.92M) [Q2]

31% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 29

48% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 31

54% less call options, than puts

Call options by funds: $424K | Put options by funds: $923K

Research analyst outlook

4 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$1
46%
upside
Avg. target
$4.75
591%
upside
High target
$10
1,356%
upside

4 analyst ratings

positive
50%
neutral
50%
negative
0%
Stephens & Co.
George Sellers
53% 1-year accuracy
9 / 17 met price target
628%upside
$5
Overweight
Maintained
9 Aug 2024
Piper Sandler
Matt O'Brien
50% 1-year accuracy
22 / 44 met price target
46%upside
$1
Neutral
Reiterated
9 Aug 2024
Stephens & Co.
George Sellers
53% 1-year accuracy
9 / 17 met price target
1,356%upside
$10
Overweight
Reiterated
25 Jun 2024
Piper Sandler
Matt O'Brien
50% 1-year accuracy
22 / 44 met price target
337%upside
$3
Neutral
Maintained
21 Jun 2024

Financial journalist opinion